Camurus announced the U.S. FDA has accepted an Investigational New Drug (IND) application for approval to initiate a Phase 3 study with CAM2029 once-monthly octreotide subcutaneous depot for treatment of acromegaly. The phase 3 trial is a randomized, double-blind,...
Hutchison China Medi-Tech (Chi-Med) reported that the independent Data Monitoring Committee (IDMC) of the Phase III pivotal study of surufatinib in advanced neuroendocrine tumors – extra-pancreatic (“SANET-ep”) has completed a planned interim analysis. The IDMC...
Data from the phase 2 DART trial, presented at the American Association for Cancer Research Annual Meeting, revealed patients with rare, high-grade neuroendocrine tumors derived clinical benefit from a combination of the immune checkpoint inhibitors ipilimumab and...
Pin It on Pinterest
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site you consent to our use of cookies.Ok
